SEC Form 4 · accession 0000899243-18-016630
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Galeota Jr.
Director
Period of report
Jun 12, 2018
Accepted (ET)
Jun 14, 2018 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $7.45 | Jun 12, 2018 | A | 25,000 | A | — | Apr 20, 2028 | Common Stock | 25,000 | 25,000 | D |
| Stock Option (right to buy)F1 | $7.45 | Jun 12, 2018 | A | 9,100 | A | Apr 20, 2019 | Apr 20, 2028 | Common Stock | 9,100 | 9,100 | D |
Explanation of responses
- F1The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.
- F2One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.